NVO
The oral-market plot thickens
Novo Nordisk just got a colder take from Berenberg, and the reason is simple: Eli Lilly is making progress in the oral side of the GLP-1 weight-loss showdown. When the market starts sounding like a sneaker drop — but for obesity drugs — every slice of share matters.
Why investors should care
Novo has been one of the biggest names in the GLP-1 boom, but the category is getting crowded fast. If Lilly keeps pulling attention in the oral market, Novo could face more pressure on growth expectations, pricing power, and the all-important “how long can this party keep going?” question.
The bigger picture
This isn’t just about one analyst note. It’s a reminder that:
- the obesity-drug market is still expanding, but competition is sharpening
- oral drugs could be the next battleground, not just injections
- investor enthusiasm can cool quickly when a rival starts looking like the better trade
Big picture: Novo still has a monster franchise, but in pharma, being the first big winner doesn’t mean you get to relax. The next act is already on stage.